475108-18-0 Suppliers

This product is a nationally controlled contraband or patented product, and the Lookchem platform doesn't provide relevant sales information.

475108-18-0 Usage

Uses

Used in Pharmaceutical Industry:
N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea is used as a potent VEGFR-1, 2, and 3 inhibitor, c-Kit and PDGFR inhibitor for its antitumor effects towards renal cell carcinoma. It suppresses angiogenesis by selectively inhibiting vascular endothelial growth factor, making it a valuable compound in the development of targeted cancer therapies.
Used in Drug Development:
N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea is used as a research tool in the development of novel VEGF receptor tyrosine kinase inhibitors. Its potent activity against multiple VEGFRs and other receptor tyrosine kinases, such as c-Kit and PDGFR, positions it as a potential candidate for further investigation in the treatment of various types of cancer.
Used in Preclinical Research:
N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)urea is utilized in preclinical studies to evaluate its efficacy and safety as a potential therapeutic agent. Its activity against multiple targets makes it an interesting compound for exploring synergistic effects in combination therapies and for identifying potential off-target effects that may impact its clinical utility.

In vitro

AV-951 is a novel quinoline-urea derivative. AV-951 blocks VEGF-dependent activation of mitogen-activated protein kinases and proliferation of endothelial cells.

In vivo

In vivo studies show that AV-951 also decreases the micro vessel density and suppresses VEGFR2 phosphorylation levels in tumor xenografts, especially at a concentration of 1mg/kg (p.o. administration). AV-951 shows almost complete inhibition of tumor xenografts growth (TGI>85%) in athymic rats. Another study in rat peritoneal disseminated tumor model shows that AV-951 could prolong the survival of the tumor-bearing rats with the MST of 53.5 days. AV-951 displays antitumor activity against many human tumor xenografts including lung, breast, colon, ovarian, pancreas and prostate cancer.

Mechanism of action

Tivozanib is a ?tyrosine kinase inhibitor that exerts its actions by inhibiting the ?phosphorylation of vascular endothelial growth factor receptor ?(VEGFR)-1, VEGFR-2 and VEGFR-3 and inhibits other kinases such as c-kit ?and platelet derived growth factor beta (PDGFR β).

Side effects

diarrheanauseavomitingfatigueloss of appetiteweight lossvoice hoarsenessback painmouth sorescoughshortness of breath

Synthesis

The synthesis of?Tivozanib is as follows:Phenyl chlorocarbonate (601 g) was added dropwise to 3-amino-5-methylisoxazole (377 g), pyridine (1215 g), and N,N-dimethylacetamide (4 L) at 0°C, and the mixture was stirred at 20°C for 2 hr. 4-[(4-Amino-3-chlorophenol)oxy]-6,7-dimethoxyquinoline (847 g) was added to the reaction solution, and the mixture was stirred at 80°C for 5 hr. The reaction solution was cooled to 5°C. Thereafter, methanol (8.5 L) and water (8.5 L) were added thereto, and the mixture was neutralized with an aqueous sodium hydroxide solution. The resultant precipitate was collected by filtration, and the filtered product was slurried in water (8.5 L) for washing. The slurry was filtered, and the filtered product was then dried under the reduced pressure to give Tivozanib (1002 g, yield 86.1%).

Check Digit Verification of cas no

The CAS Registry Mumber 475108-18-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,5,1,0 and 8 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 475108-18:
(8*4)+(7*7)+(6*5)+(5*1)+(4*0)+(3*8)+(2*1)+(1*8)=150
150 % 10 = 0
So 475108-18-0 is a valid CAS Registry Number.

475108-18-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name	1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea

1.2 Other means of identification

Product number	-
Other names	KRN-951

1.3 Recommended use of the chemical and restrictions on use

Identified uses	For industry use only.
Uses advised against	no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number	-
Service hours	Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:475108-18-0 SDS

475108-18-0Upstream product

475108-18-0Downstream Products

682745-43-3 Tivozanib hydrochloride

475108-18-0Relevant articles and documents

Synthesis process of VEGFR inhibitor tevozanib

-

, (2022/03/27)

The invention relates to a synthesis process of a VEGFR (vascular endothelial growth factor receptor) inhibitor tevozanib. According to the invention, commercially available raw materials are subjected to a halogenation reaction, an esterification reaction and an addition reaction to synthesize a target product. Generally speaking, according to the synthetic route and the synthetic process, the synthetic steps are simplified, the reaction yield of each step is high, the treatment after the reaction is simple, pulping purification is mostly adopted for purification, the use of column chromatography is avoided, the operation process is simple and cheap, and the synthetic route and the synthetic process are favorably applied to industrial mass production.

Preparation method of VEGFR inhibitor tevozanib

-

Paragraph 0037; 0056-0064, (2022/03/27)

The invention relates to a preparation method of a VEGFR (vascular endothelial growth factor receptor) inhibitor tevozanib. Compared with the prior art, according to the preparation method, the compound shown in the formula 1 and the compound shown in the formula 2 are selected to react, the reaction reagent compound shown in the formula 3 is prepared firstly, then the reaction reagent compound shown in the formula 3 and the hydroxyl of the compound shown in the formula 4 are subjected to the substitution reaction, the reaction site of the reaction is single, the yield is excellent, and reaction purification is convenient; the method provided by the invention has the advantages of simple operation process, low purification cost and high overall yield, and is suitable for industrial large-scale production of bulk pharmaceutical chemicals, and the process steps for synthesizing and preparing the tevozanib are simplified.

Preparation method for Tivozanib

-

Paragraph 0022; 0023; 0025, (2017/08/29)

The invention belongs to the technical field of the biological medicine, and particularly relates to a preparation method for Tivozanib. The preparation method comprises the following steps: firstly using N-[2-chlorine-4-hydroxy-phenyl]-N'-(5-methyl-3-isoxazolyl)-urea and 4-chlorine-6,7-dimethoxy quinolin as raw materials, reacting under the alkaline condition to obtain an intermediate product 4-[(4-amino-3-chlorophenol)-oxy]-6,7-dimethoxy quinolin, and reacting with 3-amino-5-methylisoxazole and N,N'-carbonyldiimidazole, to obtain a target product of the Tivozanib. Compared with the prior art, the preparation method has the beneficial effect. The used raw materials in the preparation process are easily obtained, the prepared Tivozanib has high purity (more than 99.65%) and the most of the contained impurities are the raw materials in the preparation process. the ingredients are clear relatively, and there are less harmful by-products.

A new and practical synthesis of tivozanib

Zhu, Chunping,Mao, Yongjun,Wang, Han,Xu, Jingli

, p. 1882 - 1887 (2016/11/06)

New and improved synthetic route of tivozanib is described on a hectogram scale. An reduction cyclization process to prepare the key intermediate 6,7-dimethoxyquinolin-4-ol from the 3-(dimethylamino)-1-(2-nitrophenyl)prop-2-en-1-one compound at H2/Ni cond

N-[2-CHLORO-4-(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM

-

Page/Page column 20, (2010/02/13)

The present invention provides a crystal of a pharmaceutically acceptable salt of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-m ethyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.

Quinoline derivatives and quinazoline derivatives having azolyl group

-

, (2008/06/13)

An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein X and

CAS

475108-18-0